Discover the science behind every claim

Discover the science behind every claim

The OS-01 Peptide

Skin barrier

The OS-01 peptide improves skin's barrier function.

Shown in a 12-week clinical study performed by a third party research organization with 22 participants, and measured with a vapometer. Effects of the peptide were isolated by evaluating the difference in barrier function between skin treated with OS-01 FACE versus an identical formulation without the OS-01 peptide (vehicle formulation). A significant improvement was observed between skin treated with OS-01 FACE versus the vehicle formulation. (Zonari, A., et al. Journal of Cosmetic Dermatology, 2024)
Hydration

The OS-01 peptide improves skin hydration retention.

Shown in a 12-week clinical study performed by a third party research organization with 22 participants, in which trans epidermal water loss (TEWL) was measured with a vapometer. Effects of the peptide were isolated by evaluating the difference in barrier function between skin treated with OS-01 FACE versus an identical formulation without the OS-01 peptide (vehicle formulation). A significant improvement was observed between skin treated with OS-01 FACE versus the vehicle formulation. (Zonari, A., et al. Journal of Cosmetic Dermatology, 2024)

Skin smoothness / texture

The OS-01 peptide improves skin’s texture.

Shown in a 12-week clinical study performed by a third party research organization with 22 participants, and measured with an Antera 3D. Effects of the peptide were isolated by evaluating the difference in texture between skin treated with OS-01 FACE versus an identical formulation without the OS-01 peptide (vehicle formulation). A significant improvement was observed between skin treated with OS-01 FACE versus the vehicle formulation. (Zonari, A., et al. Journal of Cosmetic Dermatology, 2024)

Wrinkles

The OS-01 peptide can reduce wrinkles.

Shown in a 12-week clinical study performed by a third party research organization with 22 participants, and measured with an Antera 3D. Effects of the peptide were isolated by evaluating the difference in wrinkle indentation between skin treated with OS-01 FACE versus an identical formulation without the OS-01 peptide (vehicle formulation). A close to significant reduction (p=0.072) was observed between skin treated with OS-01 FACE versus the vehicle formulation. (Zonari, A., et al. Journal of Cosmetic Dermatology, 2024)

Radiance

The OS-01 peptide can improve skin radiance.

Shown in a 12-week clinical study performed by a third party research organization with 22 participants, and measured with VISIA imaging software. Effects of the peptide were isolated by evaluating the difference in skin radiance between skin treated with OS-01 FACE versus an identical formulation without the OS-01 peptide (vehicle formulation). A reduction (not statistically significant) was observed between skin treated with OS-01 FACE versus the vehicle formulation. (Zonari, A., et al. Journal of Cosmetic Dermatology, 2024)

Age Reversal

The OS-01 peptide reverses skin’s biological age.

Measured in lab studies on human skin samples using MolClock, OneSkin’s proprietary algorithm that predicts skin’s biological age. Skin treated with the OS-01 peptide displayed a significant decrease in skin’s biological age compared to skin with no treatment. (Zonari, A., et al. npj Aging, 2023) (Boroni, M. et al. Clinical Epigenetics, 2020)

Cellular senescence

The OS-01 peptide reduces senescent burden / senescent cells / cellular senescence in skin.The OS-01 peptide switches off senescent cells.The OS-01 peptide most likely prevents pre-senescent cells from progressing to late-senescent cells, thereby reducing SASP-secreting cells and preventing the spread and accumulation of senescence in skin.

Shown in lab studies on human skin samples and/or cells by measuring the number of senescent cells via SA-Bgal staining, senescence biomarkers (CDKN2A/P16, CDKN1A, H2A.J), and SASP biomarkers (CXCL8 and IL-6). Skin treated with the OS-01 peptide displayed a significant decrease in all mentioned markers compared to skin with no treatment. (Zonari, A., et al. npj Aging, 2023)

Aging

The OS-01 peptide reduces key aging biomarkers in skin.

Shown in lab studies on human skin samples and/or cells by measuring key aging biomarkers, CDKN2A and B2M. Skin treated with the OS-01 peptide displayed a significant decrease compared to skin with no treatment. (Zonari, A., et al. npj Aging, 2023)

Repair

The OS-01 peptide can support skin’s natural repair mechanisms.

Shown in lab studies on human skin cells by measuring key DNA damage biomarker, γH2A.x. Skin treated with the OS-01 peptide displayed a significant decrease compared to skin with no treatment. (Zonari, A., et al. npj Aging, 2023)

UV-induced aging

The OS-01 peptide reduces/prevents UV-induced senescence in skin.

Shown in lab studies on human skin cells by measuring the number of senescent cells via SA-Bgal staining before and after UVB exposure. Skin that was treated with the OS-01 peptide displayed a significant decrease (42.5% less UV-induced senescent cells) compared to skin that was not treated. (Zonari, A., et al. npj Aging, 2023)

The OS-01 peptide reduces/prevents UV-induced collagen degradation in skin.

Shown in lab studies on human skin cells by measuring collagen degradation biomarker, MMP3, before and after UVB exposure. Skin treated with the OS-01 peptide displayed a decrease (not statistically significant) compared to skin with no treatment. (Zonari, A., et al. npj Aging, 2023)

Hyperpigmentation

The OS-01 peptide reduces melanin deposits in human melanocytes. Melanin is visible as skin pigmentation, therefore the OS-01 peptide may help minimize the appearance of hyperpigmentation/sun spots/age spots, and improve skin tone.

Shown in lab studies on melanocytes (human pigment-producing skin cells) by measuring levels of intracellular and extracellular melanin after chemically-induced melanin production. Cells treated with the OS-01 peptide displayed less total melanin compared to cells with no treatment and compared to cells treated with retinoic acid and kojic acid. More information can be found hereto learn more about hyperpigmentation.

Cell Proliferation / Turnover

The OS-01 peptide promotes increased cellular proliferation / turnover in skin.

Shown in lab studies on human skin samples and/or cells by measuring key cell proliferation biomarker, MKI67. Skin treated with the OS-01 peptide displayed a significant increase compared to skin with no treatment. (Zonari, A., et al. npj Aging, 2023)

Inflammation

The OS-01 peptide reduces a key inflammation biomarker (IL-6) in skin.

Shown in lab studies on human skin samples by measuring key inflammation biomarker, IL-6. Skin treated with the OS-01 peptide displayed a significant decrease compared to skin with no treatment. (Zonari, A., et al. npj Aging, 2023)

Hyaluronic Acid

The OS-01 peptide increases hyaluronic acid production in skin.

Shown in lab studies on human skin samples by measuring key hyaluronic acid production biomarker, HAS2. Skin treated with the OS-01 peptide displayed a significant increase in the epidermis compared to skin with no treatment. (Zonari, A., et al. npj Aging, 2023)

Collagen

The OS-01 peptide increases collagen production in skin.

Shown in lab studies on human skin samples by measuring key collagen production biomarker, COL1A1. Skin treated with the OS-01 peptide displayed a significant increase compared to skin with no treatment. (Zonari, A., et al. npj Aging, 2023)

Keratin

The OS-01 peptide increases keratin production in skin.

Shown in lab studies on human skin samples by measuring key keratin production biomarkers, KRT1 and KRT14. Skin treated with the OS-01 peptide displayed significant increases compared to skin with no treatment. (Zonari, A., et al. npj Aging, 2023)

Epidermal Thickness

The OS-01 peptide promotes an increase in epidermal thickness (of up to +28%).

Shown in lab studies on human skin samples by measuring epidermal thickness of histology images. Skin treated with the OS-01 peptide displayed a significant increase compared to skin with no treatment. (Zonari, A., et al. npj Aging, 2023) Increase of +28% was measured on human skin sample from a 55 year old donor treated with the OS-01 peptide. Data was measured in triplicate.

Skin barrier

The OS-01 peptide likely improves skin’s barrier function by promoting increased epidermal thickness.

Shown in lab studies on human skin samples by measuring epidermal thickness of histology images. Skin treated with the OS-01 peptide displayed a significant increase compared to skin with no treatment. (Zonari, A., et al. npj Aging, 2023) Epidermal thickness is known to be a key contributor to barrier function.

The OS-01 Peptide

Skin barrier

The OS-01 peptide improves skin's barrier function.

Shown in a 12-week clinical study performed by a third party research organization with 22 participants, and measured with a vapometer. Effects of the peptide were isolated by evaluating the difference in barrier function between skin treated with OS-01 FACE versus an identical formulation without the OS-01 peptide (vehicle formulation). A significant improvement was observed between skin treated with OS-01 FACE versus the vehicle formulation. (Zonari, A., et al. Journal of Cosmetic Dermatology, 2024)
Hydration

The OS-01 peptide improves skin hydration retention.

Shown in a 12-week clinical study performed by a third party research organization with 22 participants, in which trans epidermal water loss (TEWL) was measured with a vapometer. Effects of the peptide were isolated by evaluating the difference in barrier function between skin treated with OS-01 FACE versus an identical formulation without the OS-01 peptide (vehicle formulation). A significant improvement was observed between skin treated with OS-01 FACE versus the vehicle formulation. (Zonari, A., et al. Journal of Cosmetic Dermatology, 2024)

Skin smoothness / texture

The OS-01 peptide improves skin’s texture.

Shown in a 12-week clinical study performed by a third party research organization with 22 participants, and measured with an Antera 3D. Effects of the peptide were isolated by evaluating the difference in texture between skin treated with OS-01 FACE versus an identical formulation without the OS-01 peptide (vehicle formulation). A significant improvement was observed between skin treated with OS-01 FACE versus the vehicle formulation. (Zonari, A., et al. Journal of Cosmetic Dermatology, 2024)

Wrinkles

The OS-01 peptide can reduce wrinkles.

Shown in a 12-week clinical study performed by a third party research organization with 22 participants, and measured with an Antera 3D. Effects of the peptide were isolated by evaluating the difference in wrinkle indentation between skin treated with OS-01 FACE versus an identical formulation without the OS-01 peptide (vehicle formulation). A close to significant reduction (p=0.072) was observed between skin treated with OS-01 FACE versus the vehicle formulation. (Zonari, A., et al. Journal of Cosmetic Dermatology, 2024)

Radiance

The OS-01 peptide can improve skin radiance.

Shown in a 12-week clinical study performed by a third party research organization with 22 participants, and measured with VISIA imaging software. Effects of the peptide were isolated by evaluating the difference in skin radiance between skin treated with OS-01 FACE versus an identical formulation without the OS-01 peptide (vehicle formulation). A reduction (not statistically significant) was observed between skin treated with OS-01 FACE versus the vehicle formulation. (Zonari, A., et al. Journal of Cosmetic Dermatology, 2024)

Age Reversal

The OS-01 peptide reverses skin’s biological age.

Measured in lab studies on human skin samples using MolClock, OneSkin’s proprietary algorithm that predicts skin’s biological age. Skin treated with the OS-01 peptide displayed a significant decrease in skin’s biological age compared to skin with no treatment. (Zonari, A., et al. npj Aging, 2023) (Boroni, M. et al. Clinical Epigenetics, 2020)

Cellular senescence

The OS-01 peptide reduces senescent burden / senescent cells / cellular senescence in skin.The OS-01 peptide switches off senescent cells.The OS-01 peptide most likely prevents pre-senescent cells from progressing to late-senescent cells, thereby reducing SASP-secreting cells and preventing the spread and accumulation of senescence in skin.

Shown in lab studies on human skin samples and/or cells by measuring the number of senescent cells via SA-Bgal staining, senescence biomarkers (CDKN2A/P16, CDKN1A, H2A.J), and SASP biomarkers (CXCL8 and IL-6). Skin treated with the OS-01 peptide displayed a significant decrease in all mentioned markers compared to skin with no treatment. (Zonari, A., et al. npj Aging, 2023)

Aging

The OS-01 peptide reduces key aging biomarkers in skin.

Shown in lab studies on human skin samples and/or cells by measuring key aging biomarkers, CDKN2A and B2M. Skin treated with the OS-01 peptide displayed a significant decrease compared to skin with no treatment. (Zonari, A., et al. npj Aging, 2023)

Repair

The OS-01 peptide can support skin’s natural repair mechanisms.

Shown in lab studies on human skin cells by measuring key DNA damage biomarker, γH2A.x. Skin treated with the OS-01 peptide displayed a significant decrease compared to skin with no treatment. (Zonari, A., et al. npj Aging, 2023)

UV-induced aging

The OS-01 peptide reduces/prevents UV-induced senescence in skin.

Shown in lab studies on human skin cells by measuring the number of senescent cells via SA-Bgal staining before and after UVB exposure. Skin that was treated with the OS-01 peptide displayed a significant decrease (42.5% less UV-induced senescent cells) compared to skin that was not treated. (Zonari, A., et al. npj Aging, 2023)

The OS-01 peptide reduces/prevents UV-induced collagen degradation in skin.

Shown in lab studies on human skin cells by measuring collagen degradation biomarker, MMP3, before and after UVB exposure. Skin treated with the OS-01 peptide displayed a decrease (not statistically significant) compared to skin with no treatment. (Zonari, A., et al. npj Aging, 2023)

Hyperpigmentation

The OS-01 peptide reduces melanin deposits in human melanocytes. Melanin is visible as skin pigmentation, therefore the OS-01 peptide may help minimize the appearance of hyperpigmentation/sun spots/age spots, and improve skin tone.

Shown in lab studies on melanocytes (human pigment-producing skin cells) by measuring levels of intracellular and extracellular melanin after chemically-induced melanin production. Cells treated with the OS-01 peptide displayed less total melanin compared to cells with no treatment and compared to cells treated with retinoic acid and kojic acid. More information can be found hereto learn more about hyperpigmentation.

Cell Proliferation / Turnover

The OS-01 peptide promotes increased cellular proliferation / turnover in skin.

Shown in lab studies on human skin samples and/or cells by measuring key cell proliferation biomarker, MKI67. Skin treated with the OS-01 peptide displayed a significant increase compared to skin with no treatment. (Zonari, A., et al. npj Aging, 2023)

Inflammation

The OS-01 peptide reduces a key inflammation biomarker (IL-6) in skin.

Shown in lab studies on human skin samples by measuring key inflammation biomarker, IL-6. Skin treated with the OS-01 peptide displayed a significant decrease compared to skin with no treatment. (Zonari, A., et al. npj Aging, 2023)

Hyaluronic Acid

The OS-01 peptide increases hyaluronic acid production in skin.

Shown in lab studies on human skin samples by measuring key hyaluronic acid production biomarker, HAS2. Skin treated with the OS-01 peptide displayed a significant increase in the epidermis compared to skin with no treatment. (Zonari, A., et al. npj Aging, 2023)

Collagen

The OS-01 peptide increases collagen production in skin.

Shown in lab studies on human skin samples by measuring key collagen production biomarker, COL1A1. Skin treated with the OS-01 peptide displayed a significant increase compared to skin with no treatment. (Zonari, A., et al. npj Aging, 2023)

Keratin

The OS-01 peptide increases keratin production in skin.

Shown in lab studies on human skin samples by measuring key keratin production biomarkers, KRT1 and KRT14. Skin treated with the OS-01 peptide displayed significant increases compared to skin with no treatment. (Zonari, A., et al. npj Aging, 2023)

Epidermal Thickness

The OS-01 peptide promotes an increase in epidermal thickness (of up to +28%).

Shown in lab studies on human skin samples by measuring epidermal thickness of histology images. Skin treated with the OS-01 peptide displayed a significant increase compared to skin with no treatment. (Zonari, A., et al. npj Aging, 2023) Increase of +28% was measured on human skin sample from a 55 year old donor treated with the OS-01 peptide. Data was measured in triplicate.

Skin barrier

The OS-01 peptide likely improves skin’s barrier function by promoting increased epidermal thickness.

Shown in lab studies on human skin samples by measuring epidermal thickness of histology images. Skin treated with the OS-01 peptide displayed a significant increase compared to skin with no treatment. (Zonari, A., et al. npj Aging, 2023) Epidermal thickness is known to be a key contributor to barrier function.

OS-01 FACE

Skin barrier

OS-01 FACE improves skin barrier function by an average of +15%.

Shown in a 12-week clinical study performed by a third party research organization with 22 participants, and measured with a vapometer. A significant improvement of an average of +15% was observed in skin treated with OS-01 FACE for 12 weeks versus baseline. (Zonari, A., et al. Journal of Cosmetic Dermatology, 2024)
Hydration

OS-01 FACE improves skin hydration retention.

Shown in a 12-week clinical study performed by a third party research organization with 22 participants, in which trans epidermal water loss (TEWL) was measured with a vapometer. A significant improvement was observed in skin treated with OS-01 FACE for 12 weeks versus baseline. (Zonari, A., et al. Journal of Cosmetic Dermatology, 2024)

Elasticity

OS-01 FACE improves skin elasticity (shown in 90% of users).

Shown in a 12-week clinical study performed by a third party research organization with 22 participants, and analyzed via double-blind expert clinical grader evaluation. An improvement was observed in 90% of participants in skin treated with OS-01 FACE for 12 weeks versus baseline. (Zonari, A., et al. Journal of Cosmetic Dermatology, 2024)

Tone, radiance, pores, firmness

OS-01 FACE improves skin evenness, radiance, pores and firmness (shown in 95.5% of users).

Shown in a 12-week clinical study performed by a third party research organization with 22 participants, and analyzed via double-blind expert clinical grader evaluation. An improvement was observed in 95.5% of participants in skin treated with OS-01 FACE for 6-12 weeks versus baseline. (Zonari, A., et al. Journal of Cosmetic Dermatology, 2024, supporting information)

Fine lines + wrinkles

OS-01 FACE reduces the appearance of fine lines and wrinkles (shown in 86% of users).

Shown in a 12-week clinical study performed by a third party research organization with 22 participants, and analyzed via double-blind expert clinical grader evaluation. An improvement was observed in 86% of participants in skin treated with OS-01 FACE for 12 weeks versus baseline. (Zonari, A., et al. Journal of Cosmetic Dermatology, 2024, supporting information)

Overall appearance + smoothness

OS-01 FACE improves skin smoothness and overall appearance (shown in 100% of users).

Shown in a 12-week clinical study performed by a third party research organization with 22 participants, and analyzed via double-blind expert clinical grader evaluation. An improvement was observed in 100% of participants in skin treated with OS-01 FACE for 12 weeks versus baseline. (Zonari, A., et al. Journal of Cosmetic Dermatology, 2024, supporting information)

Hyperpigmentation

68.4% of users agree that their dark spots (hyperpigmentation) improved after using OS-01 FACE.

Shown in a 6-week clinical study performed by a third party research organization with 38 participants who self-reported improvements in dark spots (lightening of hyperpigmentation) after using OS-01 FACE compared to baseline.

Eye bags

68.4% of users agree that their eye bags improved after using OS-01 FACE.

Shown in a 6-week clinical study performed by a third party research organization with 38 participants who self-reported improvements in eye bags after using OS-01 FACE compared to baseline.

Improvement in skin issues such as acne and redness

51.8% of participants agree issues in their skin such as acne and redness improved after using OS-01 FACE.

Shown in a 6-week clinical study performed by a third party research organization with 29 participants who self-reported improvements in existing skin issues after using OS-01 FACE compared to baseline.

Skin microbiome

OS-01 FACE is clinically validated to support skin’s microbiome.

Shown in a 6-week clinical study performed by a third party research organization (HelloBiome) with 38 participants who collected samples of their facial skin microbiome before and after treatment with OS-01 FACE for 6 weeks. Using next generation sequencing and existing research, HelloBiome determined that OS-01 FACE supports skin’s microbiome because:
  • Participants displayed a significant positive shift of the microbiome grade after treatment compared to baseline
  • No significant changes in the ratio of bacteria to fungi were detected after treatment compared to baseline
To learn more, click hereto learn more about os 01 face clinically validated to support your skins microbiome.

Non-Comedogenic

OS-01 FACE is non-comedogenic.

Show in a four-week single-blind clinical study with 33 participants assessing the comedogenic potential of OS-01 FACE, OS-01 EYE, OS-01 FACE SPF (OS-01 SHIELD), and OS-01 BODY SPF by means of repeated occlusive cutaneous patch applications and follicular biopsy procedure. The positive control (lanolin) showed significantly higher follicular biopsy scores compared to the test products (p<0.05). When compared to the negative control (untreated site), there were no statistically significant changes in skin treated with the test products, clinically proving that the test products are non-comedogenic.

Sensitive Skin

OS-01 FACE is Dermatologically Tested and Safe for Sensitive Skin.

Show in a clinical study with 54 healthy volunteers by means of repeated cutaneous occlusive patch applications, after which there were no questionable reactions observed.

Epidermal thickness

OS-01 FACE promotes an increase in epidermal thickness (of +23% on average).

Shown in lab studies on human skin samples by measuring epidermal thickness of histology images. Skin treated with OS-01 FACE displayed a significant increase (average +23%) compared to skin with no treatment. (Zonari, A., et al. npj Aging, 2023, supplementary information)

Aging

OS-01 FACE reduces key aging biomarkers in skin.

Shown in lab studies on human skin samples by measuring key aging biomarkers, CDKN2A and B2M. Skin treated with OS-01 FACE displayed a significant decrease compared to skin with no treatment. (Zonari, A., et al. npj Aging, 2023, supplementary information)

OS-01 FACE vs Retinol(Collagen)

OS-01 FACE and retinol both increase collagen production at similar levels in skin.

Shown in lab studies on human skin samples by measuring key collagen production biomarker, COL1A1, in skin treated with nothing, OS-01 FACE, or 1% topical retinol for 5 days. Skin treated with OS-01 FACE and retinol both displayed similar and significant increases compared to skin with no treatment. (Zonari, A., et al. npj Aging, 2023, supplementary information)

Collagen

OS-01 FACE increases collagen production in skin.

Shown in lab studies on human skin samples by measuring key collagen production biomarker, COL1A1. Skin treated with OS-01 FACE displayed a significant increase compared to skin with no treatment. (Zonari, A., et al. npj Aging, 2023, supplementary information)

OS-01 FACE can increase collagen production in skin by up to 1.4x (+40%).

Shown in lab studies on ex vivo human skin sample (70 yr) by analyzing levels of collagen in the dermis. Skin treated with OS-01 FACE displayed an increase (not statistically significant) compared to skin with no treatment. Data was measured in triplicate.

OS-01 FACE vs Retinol(Aging)

Retinol increases a key aging biomarker in skin, while OS-01 FACE does not.

Shown in lab studies on human skin samples by measuring key aging biomarker, CDKN2A, in skin treated with nothing, OS-01 FACE, or 1% topical retinol for 5 days. Skin treated with retinol displayed a significant increase compared to skin treated with OS-01 FACE and skin with no treatment, while skin treated with OS-01 FACE displayed no change compared to skin with no treatment. (Zonari, A., et al. npj Aging, 2023, supplementary information)

Cell Proliferation / Turnover

OS-01 FACE promotes increased cellular proliferation / turnover in skin.

Shown in lab studies on human skin samples by measuring key cell proliferation biomarkers, MKI67 and Ki-67. Skin treated with OS-01 FACE displayed significant increases compared to skin with no treatment. (Zonari, A., et al. npj Aging, 2023)

OS-01 FACE vs Retinol(Cell Proliferation and Epidermal Thickness)

OS-01 FACE increases a key cell proliferation biomarker in the dermis, and increases skin’s epidermal thickness, while retinol does not.

Shown in lab studies on human skin samples by measuring key cell proliferation biomarker, MKi67, and epidermal thickness in skin treated with nothing, OS-01 FACE, or 1% topical retinol for 5 days. Skin treated with OS-01 FACE displayed a significant increase compared to skin with no treatment, while skin treated with retinol displayed no change compared to skin with no treatment. (Zonari, A., et al. npj Aging, 2023, supplementary information)Note: Skin that had been treated with OS-01 FACE and retinol both displayed significant increases in cell proliferation biomarker, MKi67, in the epidermis compared to skin with no treatment. (Zonari, A., et al. npj Aging, 2023, supplementary information) These results represent acute responses to the products and may not reflect long-term results.

OS-01 FACE

Skin barrier

OS-01 FACE improves skin barrier function by an average of +15%.

Shown in a 12-week clinical study performed by a third party research organization with 22 participants, and measured with a vapometer. A significant improvement of an average of +15% was observed in skin treated with OS-01 FACE for 12 weeks versus baseline. (Zonari, A., et al. Journal of Cosmetic Dermatology, 2024)
Hydration

OS-01 FACE improves skin hydration retention.

Shown in a 12-week clinical study performed by a third party research organization with 22 participants, in which trans epidermal water loss (TEWL) was measured with a vapometer. A significant improvement was observed in skin treated with OS-01 FACE for 12 weeks versus baseline. (Zonari, A., et al. Journal of Cosmetic Dermatology, 2024)

Elasticity

OS-01 FACE improves skin elasticity (shown in 90% of users).

Shown in a 12-week clinical study performed by a third party research organization with 22 participants, and analyzed via double-blind expert clinical grader evaluation. An improvement was observed in 90% of participants in skin treated with OS-01 FACE for 12 weeks versus baseline. (Zonari, A., et al. Journal of Cosmetic Dermatology, 2024)

Tone, radiance, pores, firmness

OS-01 FACE improves skin evenness, radiance, pores and firmness (shown in 95.5% of users).

Shown in a 12-week clinical study performed by a third party research organization with 22 participants, and analyzed via double-blind expert clinical grader evaluation. An improvement was observed in 95.5% of participants in skin treated with OS-01 FACE for 6-12 weeks versus baseline. (Zonari, A., et al. Journal of Cosmetic Dermatology, 2024, supporting information)

Fine lines + wrinkles

OS-01 FACE reduces the appearance of fine lines and wrinkles (shown in 86% of users).

Shown in a 12-week clinical study performed by a third party research organization with 22 participants, and analyzed via double-blind expert clinical grader evaluation. An improvement was observed in 86% of participants in skin treated with OS-01 FACE for 12 weeks versus baseline. (Zonari, A., et al. Journal of Cosmetic Dermatology, 2024, supporting information)

Overall appearance + smoothness

OS-01 FACE improves skin smoothness and overall appearance (shown in 100% of users).

Shown in a 12-week clinical study performed by a third party research organization with 22 participants, and analyzed via double-blind expert clinical grader evaluation. An improvement was observed in 100% of participants in skin treated with OS-01 FACE for 12 weeks versus baseline. (Zonari, A., et al. Journal of Cosmetic Dermatology, 2024, supporting information)

Hyperpigmentation

68.4% of users agree that their dark spots (hyperpigmentation) improved after using OS-01 FACE.

Shown in a 6-week clinical study performed by a third party research organization with 38 participants who self-reported improvements in dark spots (lightening of hyperpigmentation) after using OS-01 FACE compared to baseline.

Eye bags

68.4% of users agree that their eye bags improved after using OS-01 FACE.

Shown in a 6-week clinical study performed by a third party research organization with 38 participants who self-reported improvements in eye bags after using OS-01 FACE compared to baseline.

Improvement in skin issues such as acne and redness

51.8% of participants agree issues in their skin such as acne and redness improved after using OS-01 FACE.

Shown in a 6-week clinical study performed by a third party research organization with 29 participants who self-reported improvements in existing skin issues after using OS-01 FACE compared to baseline.

Skin microbiome

OS-01 FACE is clinically validated to support skin’s microbiome.

Shown in a 6-week clinical study performed by a third party research organization (HelloBiome) with 38 participants who collected samples of their facial skin microbiome before and after treatment with OS-01 FACE for 6 weeks. Using next generation sequencing and existing research, HelloBiome determined that OS-01 FACE supports skin’s microbiome because:
  • Participants displayed a significant positive shift of the microbiome grade after treatment compared to baseline
  • No significant changes in the ratio of bacteria to fungi were detected after treatment compared to baseline
To learn more, click hereto learn more about os 01 face clinically validated to support your skins microbiome.

Non-Comedogenic

OS-01 FACE is non-comedogenic.

Show in a four-week single-blind clinical study with 33 participants assessing the comedogenic potential of OS-01 FACE, OS-01 EYE, OS-01 FACE SPF (OS-01 SHIELD), and OS-01 BODY SPF by means of repeated occlusive cutaneous patch applications and follicular biopsy procedure. The positive control (lanolin) showed significantly higher follicular biopsy scores compared to the test products (p<0.05). When compared to the negative control (untreated site), there were no statistically significant changes in skin treated with the test products, clinically proving that the test products are non-comedogenic.

Sensitive Skin

OS-01 FACE is Dermatologically Tested and Safe for Sensitive Skin.

Show in a clinical study with 54 healthy volunteers by means of repeated cutaneous occlusive patch applications, after which there were no questionable reactions observed.

Epidermal thickness

OS-01 FACE promotes an increase in epidermal thickness (of +23% on average).

Shown in lab studies on human skin samples by measuring epidermal thickness of histology images. Skin treated with OS-01 FACE displayed a significant increase (average +23%) compared to skin with no treatment. (Zonari, A., et al. npj Aging, 2023, supplementary information)

Aging

OS-01 FACE reduces key aging biomarkers in skin.

Shown in lab studies on human skin samples by measuring key aging biomarkers, CDKN2A and B2M. Skin treated with OS-01 FACE displayed a significant decrease compared to skin with no treatment. (Zonari, A., et al. npj Aging, 2023, supplementary information)

Cell Proliferation / Turnover

OS-01 FACE promotes increased cellular proliferation / turnover in skin.

Shown in lab studies on human skin samples by measuring key cell proliferation biomarkers, MKI67 and Ki-67. Skin treated with OS-01 FACE displayed significant increases compared to skin with no treatment. (Zonari, A., et al. npj Aging, 2023)

Collagen

OS-01 FACE increases collagen production in skin.

Shown in lab studies on human skin samples by measuring key collagen production biomarker, COL1A1. Skin treated with OS-01 FACE displayed a significant increase compared to skin with no treatment. (Zonari, A., et al. npj Aging, 2023, supplementary information)

OS-01 FACE can increase collagen production in skin by up to 1.4x (+40%).

Shown in lab studies on ex vivo human skin sample (70 yr) by analyzing levels of collagen in the dermis. Skin treated with OS-01 FACE displayed an increase (not statistically significant) compared to skin with no treatment. Data was measured in triplicate.

OS-01 FACE vs Retinol(Collagen)

OS-01 FACE and retinol both increase collagen production at similar levels in skin.

Shown in lab studies on human skin samples by measuring key collagen production biomarker, COL1A1, in skin treated with nothing, OS-01 FACE, or 1% topical retinol for 5 days. Skin treated with OS-01 FACE and retinol both displayed similar and significant increases compared to skin with no treatment. (Zonari, A., et al. npj Aging, 2023, supplementary information)

OS-01 FACE vs Retinol(Aging)

Retinol increases a key aging biomarker in skin, while OS-01 FACE does not.

Shown in lab studies on human skin samples by measuring key aging biomarker, CDKN2A, in skin treated with nothing, OS-01 FACE, or 1% topical retinol for 5 days. Skin treated with retinol displayed a significant increase compared to skin treated with OS-01 FACE and skin with no treatment, while skin treated with OS-01 FACE displayed no change compared to skin with no treatment. (Zonari, A., et al. npj Aging, 2023, supplementary information)

OS-01 FACE vs Retinol(Cell Proliferation and Epidermal Thickness)

OS-01 FACE increases a key cell proliferation biomarker in the dermis, and increases skin’s epidermal thickness, while retinol does not.

Shown in lab studies on human skin samples by measuring key cell proliferation biomarker, MKi67, and epidermal thickness in skin treated with nothing, OS-01 FACE, or 1% topical retinol for 5 days. Skin treated with OS-01 FACE displayed a significant increase compared to skin with no treatment, while skin treated with retinol displayed no change compared to skin with no treatment. (Zonari, A., et al. npj Aging, 2023, supplementary information)Note: Skin that had been treated with OS-01 FACE and retinol both displayed significant increases in cell proliferation biomarker, MKi67, in the epidermis compared to skin with no treatment. (Zonari, A., et al. npj Aging, 2023, supplementary information) These results represent acute responses to the products and may not reflect long-term results.

OS-01 EYE

Skin barrier

OS-01 EYE improves skin barrier function by an average of +17%.

Shown in a 12-week clinical study performed by a third party research organization with 22 participants, in which trans-epidermal water loss (TEWL) was measured with a vapometer. A significant improvement of an average of +17% was measured in 70% of participants in skin treated with OS-01 EYE for 12 weeks versus baseline. (OneSkin manuscript in preparation, explore the study hereto learn more about better elasticity more firmness discover os 01 eyes clinical results)
Hydration

OS-01 EYE improves skin hydration. (Observed by 92% of users and shown in 87.5% of users with an average improvement of +32%.)

Shown in a 12-week clinical study performed by a third party research organization with 22 participants, in which participants self-reported results and skin hydration was measured with a corneometer. 92% of respondents reported an improvement in skin hydration and a significant improvement of avg +32% was measured in 87.5% of participants from corneometer measurements in skin treated with OS-01 EYE for 4-12 weeks versus baseline. (OneSkin manuscript in preparation, explore the study hereto learn more about better elasticity more firmness discover os 01 eyes clinical results)

Elasticity

OS-01 EYE improves skin elasticity. (Shown in 86% of users with an average improvement of +24%.)

Shown in a 12-week clinical study performed by a third party research organization with 22 participants, in which elasticity was measured with a cutometer. A significant improvement of avg +24% was measured in 86% of participants in skin treated with OS-01 EYE for 12 weeks versus baseline. (OneSkin manuscript in preparation, explore the study hereto learn more about better elasticity more firmness discover os 01 eyes clinical results)

Firmness

OS-01 EYE improves skin firmness. (Observed by 82% of users and shown in 73% of users with an average improvement of +10%.)

Shown in a 12-week clinical study performed by a third party research organization with 22 participants, in which participants self-reported results and firmness was measured with a cutometer. 82% respondents reported an improvement in skin firmness/elasticity and a significant improvement of avg +10% was measured in 73% of participants in skin treated with OS-01 EYE for 12 weeks versus baseline. (OneSkin manuscript in preparation, explore the study hereto learn more about better elasticity more firmness discover os 01 eyes clinical results)

Tone + Texture

OS-01 EYE improves skin tone and texture. (Observed by 96% of users.)

Shown in a 12-week clinical study performed by a third party research organization with 22 participants, in which 96% of respondents reported an improvement in skin tone and texture in skin treated with OS-01 EYE for 4 weeks versus baseline. (OneSkin manuscript in preparation, explore the study hereto learn more about better elasticity more firmness discover os 01 eyes clinical results)

Radiance

OS-01 EYE improves skin radiance. (Observed by 92% of users.)

Shown in a 12-week clinical study performed by a third party research organization with 22 participants, in which 92% of respondents reported an improvement in skin radiance in skin treated with OS-01 EYE for 4 weeks versus baseline. (OneSkin manuscript in preparation, explore the study hereto learn more about better elasticity more firmness discover os 01 eyes clinical results)

Puffiness

OS-01 EYE reduces eye puffiness. (Observed by 77% of users.)

Shown in a 12-week clinical study performed by a third party research organization with 22 participants, in which 77% of respondents reported an improvement in eye puffiness in skin treated with OS-01 EYE for 12 weeks versus baseline. (OneSkin manuscript in preparation, explore the study hereto learn more about better elasticity more firmness discover os 01 eyes clinical results)

Overall appearance

OS-01 EYE improves skin’s overall appearance. (Observed by 96% of users.)

Shown in a 12-week clinical study performed by a third party research organization with 22 participants, in which 96% of respondents reported an improvement in overall appearance in skin treated with OS-01 EYE for 4 weeks versus baseline. (OneSkin manuscript in preparation, explore the study hereto learn more about better elasticity more firmness discover os 01 eyes clinical results)

NON-COMEDOGENIC

OS-01 EYE is non-comedogenic.

Show in a four-week single-blind clinical study with 33 participants assessing the comedogenic potential of OS-01 FACE, OS-01 EYE, OS-01 FACE SPF (OS-01 SHIELD), and OS-01 BODY SPF by means of repeated occlusive cutaneous patch applications and follicular biopsy procedure. The positive control (lanolin) showed significantly higher follicular biopsy scores compared to the test products (p<0.05). When compared to the negative control (untreated site), there were no statistically significant changes in skin treated with the test products, clinically proving that the test products are non-comedogenic.

Sensitive Skin

OS-01 EYE is Dermatologically Tested and Safe for Sensitive Skin.

Show in a clinical study with 54 healthy volunteers by means of repeated cutaneous occlusive patch applications, after which there were no questionable reactions observed.

Cellular senescence

OS-01 EYE reduces a key cellular senescence and aging biomarker in skin.

Shown in lab studies on ex vivo human eyelid skin samples (42, 59, 84 yr) by measuring key senescence and aging biomarker, CDKN2A. Skin treated with OS-01 EYE displayed a significant decrease in CDKN2A compared to skin with no treatment.

Collagen

OS-01 EYE improves collagen production and reduces collagen degradation in skin.

Shown in lab studies on ex vivo human eyelid skin samples (42, 59, 84 yr) by measuring key collagen production biomarker, COL1A1, and key collagen degradation biomarker, MMP1. Skin treated with OS-01 EYE displayed a close to significant (p=0.11) increase in COL1A1 and a significant decrease in MMP1 (p=0.0445) compared to skin with no treatment.

OS-01 EYE increases collagen by up to 2.3x (230%).

Shown in lab studies on ex vivo human eyelid skin samples (70 yr) by analyzing levels of collagen in skin treated with OS-01 EYE compared to no treatment. Skin treated with OS-01 EYE displayed a significant increase compared to skin with no treatment. Data was measured in triplicate.

Inflammation

OS-01 EYE reduces a key inflammation biomarker in skin.

Shown in lab studies on ex vivo human eyelid skin samples (42, 59, 84 yr) by measuring key inflammation biomarker, IL-8. Skin treated with OS-01 EYE displayed a significant decrease in IL-8 compared to skin with no treatment.

OS-01 EYE

Hydration

OS-01 EYE improves skin hydration. (Observed by 92% of users and shown in 87.5% of users with an average improvement of +32%.)

Shown in a 12-week clinical study performed by a third party research organization with 22 participants, in which participants self-reported results and skin hydration was measured with a corneometer. 92% of respondents reported an improvement in skin hydration and a significant improvement of avg +32% was measured in 87.5% of participants from corneometer measurements in skin treated with OS-01 EYE for 4-12 weeks versus baseline. (OneSkin manuscript in preparation, explore the study hereto learn more about better elasticity more firmness discover os 01 eyes clinical results)
Elasticity

OS-01 EYE improves skin elasticity. (Shown in 86% of users with an average improvement of +24%.)

Shown in a 12-week clinical study performed by a third party research organization with 22 participants, in which elasticity was measured with a cutometer. A significant improvement of avg +24% was measured in 86% of participants in skin treated with OS-01 EYE for 12 weeks versus baseline. (OneSkin manuscript in preparation, explore the study hereto learn more about better elasticity more firmness discover os 01 eyes clinical results)

Firmness

OS-01 EYE improves skin firmness. (Observed by 82% of users and shown in 73% of users with an average improvement of +10%.)

Shown in a 12-week clinical study performed by a third party research organization with 22 participants, in which participants self-reported results and firmness was measured with a cutometer. 82% respondents reported an improvement in skin firmness/elasticity and a significant improvement of avg +10% was measured in 73% of participants in skin treated with OS-01 EYE for 12 weeks versus baseline. (OneSkin manuscript in preparation, explore the study hereto learn more about better elasticity more firmness discover os 01 eyes clinical results)

Skin barrier

OS-01 EYE improves skin barrier function by an average of +17%.

Shown in a 12-week clinical study performed by a third party research organization with 22 participants, in which trans-epidermal water loss (TEWL) was measured with a vapometer. A significant improvement of an average of +17% was measured in 70% of participants in skin treated with OS-01 EYE for 12 weeks versus baseline. (OneSkin manuscript in preparation, explore the study hereto learn more about better elasticity more firmness discover os 01 eyes clinical results)

Tone + Texture

OS-01 EYE improves skin tone and texture. (Observed by 96% of users.)

Shown in a 12-week clinical study performed by a third party research organization with 22 participants, in which 96% of respondents reported an improvement in skin tone and texture in skin treated with OS-01 EYE for 4 weeks versus baseline. (OneSkin manuscript in preparation, explore the study hereto learn more about better elasticity more firmness discover os 01 eyes clinical results)

Radiance

OS-01 EYE improves skin radiance. (Observed by 92% of users.)

Shown in a 12-week clinical study performed by a third party research organization with 22 participants, in which 92% of respondents reported an improvement in skin radiance in skin treated with OS-01 EYE for 4 weeks versus baseline. (OneSkin manuscript in preparation, explore the study hereto learn more about better elasticity more firmness discover os 01 eyes clinical results)

Puffiness

OS-01 EYE reduces eye puffiness. (Observed by 77% of users.)

Shown in a 12-week clinical study performed by a third party research organization with 22 participants, in which 77% of respondents reported an improvement in eye puffiness in skin treated with OS-01 EYE for 12 weeks versus baseline. (OneSkin manuscript in preparation, explore the study hereto learn more about better elasticity more firmness discover os 01 eyes clinical results)

Overall appearance

OS-01 EYE improves skin’s overall appearance. (Observed by 96% of users.)

Shown in a 12-week clinical study performed by a third party research organization with 22 participants, in which 96% of respondents reported an improvement in overall appearance in skin treated with OS-01 EYE for 4 weeks versus baseline. (OneSkin manuscript in preparation, explore the study hereto learn more about better elasticity more firmness discover os 01 eyes clinical results)

NON-COMEDOGENIC

OS-01 EYE is non-comedogenic.

Show in a four-week single-blind clinical study with 33 participants assessing the comedogenic potential of OS-01 FACE, OS-01 EYE, OS-01 FACE SPF (OS-01 SHIELD), and OS-01 BODY SPF by means of repeated occlusive cutaneous patch applications and follicular biopsy procedure. The positive control (lanolin) showed significantly higher follicular biopsy scores compared to the test products (p<0.05). When compared to the negative control (untreated site), there were no statistically significant changes in skin treated with the test products, clinically proving that the test products are non-comedogenic.

Sensitive Skin

OS-01 EYE is Dermatologically Tested and Safe for Sensitive Skin.

Show in a clinical study with 54 healthy volunteers by means of repeated cutaneous occlusive patch applications, after which there were no questionable reactions observed.

Collagen

OS-01 EYE improves collagen production and reduces collagen degradation in skin.

Shown in lab studies on ex vivo human eyelid skin samples (42, 59, 84 yr) by measuring key collagen production biomarker, COL1A1, and key collagen degradation biomarker, MMP1. Skin treated with OS-01 EYE displayed a close to significant (p=0.11) increase in COL1A1 and a significant decrease in MMP1 (p=0.0445) compared to skin with no treatment.

OS-01 EYE increases collagen by up to 2.3x (230%).

Shown in lab studies on ex vivo human eyelid skin samples (70 yr) by analyzing levels of collagen in skin treated with OS-01 EYE compared to no treatment. Skin treated with OS-01 EYE displayed a significant increase compared to skin with no treatment. Data was measured in triplicate.

Cellular senescence

OS-01 EYE reduces a key cellular senescence and aging biomarker in skin.

Shown in lab studies on ex vivo human eyelid skin samples (42, 59, 84 yr) by measuring key senescence and aging biomarker, CDKN2A. Skin treated with OS-01 EYE displayed a significant decrease in CDKN2A compared to skin with no treatment.

Inflammation

OS-01 EYE reduces a key inflammation biomarker in skin.

Shown in lab studies on ex vivo human eyelid skin samples (42, 59, 84 yr) by measuring key inflammation biomarker, IL-8. Skin treated with OS-01 EYE displayed a significant decrease in IL-8 compared to skin with no treatment.

OS-01 BODY

Skin barrier

OS-01 BODY improves skin barrier. (Average +41.49% forearm; average +34.73% upper arm.)

Shown in a 12-week clinical study performed by a third party research organization with 27 participants, in which trans-epidermal water loss (TEWL) was measured with a tewameter in skin treated with OS-01 BODY 12 weeks versus baseline. Improvement in barrier function was measured in a significant number of participants, with an avg improvement of +41.49% on forearm skin and +34.73% on the upper arm skin. (OneSkin manuscript in process of publication, explore the study hereto learn more about os 01 body 12 week clinically validated results)
Hydration

OS-01 BODY improves skin hydration. (Observed by 93% of users and shown in a significant number of users, with and average improvement of +38.34% on forearm skin and +38.39% on upper arm skin.)

Shown in a 12-week clinical study performed by a third party research organization with 27 participants, in which participants self-reported results and skin hydration was measured with a corneometer in skin treated with OS-01 BODY 12 weeks versus baseline. 93% of respondents reported an improvement in skin hydration. Improvement in skin hydration was measured in a significant number of participants, with an avg improvement of +38.34% on forearm skin and +38.39% on the upper arm skin. (OneSkin manuscript in process of publication, explore the study hereto learn more about os 01 body 12 week clinically validated results)

Texture

OS-01 BODY improves skin texture. (Observed by 70% of users.)

Shown in a 12-week clinical study performed by a third party research organization with 27 participants, in which 70% of participants reported improved skin texture after using OS-01 BODY for 12 weeks compared to baseline. (OneSkin manuscript in process of peer-reviewed publication, explore the study hereto learn more about os 01 body 12 week clinically validated results)

General appearance

OS-01 BODY improves skin’s general appearance. (Observed by 72% of users.)

Shown in a 12-week clinical study performed by a third party research organization with 27 participants, in which 72% of participants reported an improvement in skin’s general appearance after using OS-01 BODY for 12 weeks compared to baseline. (OneSkin manuscript in process of peer-reviewed publication)

Inflammation

OS-01 BODY may help reduce circulating/systemic inflammation.

Shown in a 12-week clinical study performed by a third party research organization with 27 participants, in which blood samples of participants were collected at baseline and after 12 weeks of using OS-01 BODY. Participants experienced a general decrease in cytokine levels and a significant decrease in circulating IL-8 compared to baseline. (OneSkin manuscript in process of peer-reviewed publication, explore the study hereto learn more about os 01 body 12 week clinically validated results)

Biological age

OS-01 BODY can pause biological aging.

Shown in a 12-week clinical study performed by a third party research organization with 52 participants, in which blood samples of participants were collected at baseline and after 12 weeks of using OS-01 BODY or a control formulation (an average drugstore moisturizer). The biological age of participants was measured using GlycanAge at baseline and after 12 weeks of using OS-01 BODY or the control formulation. The biological age of participants using OS-01 BODY (n=27) did not change, while the biological age of participants using the control formula (n=25) increased compared to baseline. (OneSkin manuscript in process of peer-reviewed publication, explore the study hereto learn more about os 01 body 12 week clinically validated results)

OS-01 Peptide Penetration into Bloodstream

The OS-01 peptide does not accumulate in the bloodstream when applied topically.

Shown in a 12-week clinical study performed by a third party research organization with 52 participants, in which blood samples of participants were collected at baseline and after 12 weeks of using OS-01 BODY daily. Using mass spectroscopy and no peptide was detected in plasma samples after 12 weeks. (OneSkin manuscript in process of peer-reviewed publication)

Sensitive Skin

OS-01 BODY is Dermatologically Tested and Safe for Sensitive Skin.

Show in a clinical study with 54 healthy volunteers by means of repeated cutaneous occlusive patch applications, after which there were no questionable reactions observed.

Epidermal Thickness

OS-01 BODY promotes an increase in epidermal thickness (of up to 40%).

Shown in lab studies on ex vivo human skin samples (44 yr) by measuring epidermal thickness of histology images. Skin treated with OS-01 BODY displayed a significant increase of +40% compared to skin with no treatment. Data was measured in triplicate.

OS-01 BODY

Hydration

OS-01 BODY improves skin hydration. (Observed by 93% of users and shown in a significant number of users, with and average improvement of +38.34% on forearm skin and +38.39% on upper arm skin.)

Shown in a 12-week clinical study performed by a third party research organization with 27 participants, in which participants self-reported results and skin hydration was measured with a corneometer in skin treated with OS-01 BODY 12 weeks versus baseline. 93% of respondents reported an improvement in skin hydration. Improvement in skin hydration was measured in a significant number of participants, with an avg improvement of +38.34% on forearm skin and +38.39% on the upper arm skin. (OneSkin manuscript in process of publication, explore the study hereto learn more about os 01 body 12 week clinically validated results)
Skin barrier

OS-01 BODY improves skin barrier. (Average +41.49% forearm; average +34.73% upper arm.)

Shown in a 12-week clinical study performed by a third party research organization with 27 participants, in which trans-epidermal water loss (TEWL) was measured with a tewameter in skin treated with OS-01 BODY 12 weeks versus baseline. Improvement in barrier function was measured in a significant number of participants, with an avg improvement of +41.49% on forearm skin and +34.73% on the upper arm skin. (OneSkin manuscript in process of publication, explore the study hereto learn more about os 01 body 12 week clinically validated results)

Texture

OS-01 BODY improves skin texture. (Observed by 70% of users.)

Shown in a 12-week clinical study performed by a third party research organization with 27 participants, in which 70% of participants reported improved skin texture after using OS-01 BODY for 12 weeks compared to baseline. (OneSkin manuscript in process of peer-reviewed publication, explore the study hereto learn more about os 01 body 12 week clinically validated results)

General appearance

OS-01 BODY improves skin’s general appearance. (Observed by 72% of users.)

Shown in a 12-week clinical study performed by a third party research organization with 27 participants, in which 72% of participants reported an improvement in skin’s general appearance after using OS-01 BODY for 12 weeks compared to baseline. (OneSkin manuscript in process of peer-reviewed publication)

Inflammation

OS-01 BODY may help reduce circulating/systemic inflammation.

Shown in a 12-week clinical study performed by a third party research organization with 27 participants, in which blood samples of participants were collected at baseline and after 12 weeks of using OS-01 BODY. Participants experienced a general decrease in cytokine levels and a significant decrease in circulating IL-8 compared to baseline. (OneSkin manuscript in process of peer-reviewed publication, explore the study hereto learn more about os 01 body 12 week clinically validated results)

Biological age

OS-01 BODY can pause biological aging.

Shown in a 12-week clinical study performed by a third party research organization with 52 participants, in which blood samples of participants were collected at baseline and after 12 weeks of using OS-01 BODY or a control formulation (an average drugstore moisturizer). The biological age of participants was measured using GlycanAge at baseline and after 12 weeks of using OS-01 BODY or the control formulation. The biological age of participants using OS-01 BODY (n=27) did not change, while the biological age of participants using the control formula (n=25) increased compared to baseline. (OneSkin manuscript in process of peer-reviewed publication, explore the study hereto learn more about os 01 body 12 week clinically validated results)

OS-01 Peptide Penetration into Bloodstream

The OS-01 peptide does not accumulate in the bloodstream when applied topically.

Shown in a 12-week clinical study performed by a third party research organization with 52 participants, in which blood samples of participants were collected at baseline and after 12 weeks of using OS-01 BODY daily. Using mass spectroscopy and no peptide was detected in plasma samples after 12 weeks. (OneSkin manuscript in process of peer-reviewed publication)

Sensitive Skin

OS-01 BODY is Dermatologically Tested and Safe for Sensitive Skin.

Show in a clinical study with 54 healthy volunteers by means of repeated cutaneous occlusive patch applications, after which there were no questionable reactions observed.

Epidermal Thickness

OS-01 BODY promotes an increase in epidermal thickness (of up to 40%).

Shown in lab studies on ex vivo human skin samples (44 yr) by measuring epidermal thickness of histology images. Skin treated with OS-01 BODY displayed a significant increase of +40% compared to skin with no treatment. Data was measured in triplicate.

OS-01 FACE SPF (OS-01 SHIELD)

Sunburn

OS-01 FACE SPF is more effective at protecting against UV-induced erythema (sunburn) compared to a top dermatologist recommended brand.

Shown in a clinical study performed by a third party research organization with 30 participants, measuring erythema levels on skin protected with OS-01 FACE SPF versus a top dermatologist recommended brand before and 24 hours after UV exposure.
UV-Induced Pigmentation

OS-01 FACE SPF is more effective at protecting against UV-induced pigmentation compared to a top dermatologist recommended brand.

Shown in a clinical study performed by a third party research organization with 30 participants, measuring pigmentation levels on skin protected with OS-01 FACE SPF versus a top dermatologist recommended brand before and 24 hours after UV exposure.

Feel / visual benefits

Skin feels moisturized after using OS-01 FACE SPF (91% of users agree)Skin feels nourished after using OS-01 FACE SPF (87% of users agree)OS-01 FACE SPF spreads easily (80% of users agree)Skin feels more hydrated after using OS-01 FACE SPF (78% of users agree)OS-01 FACE SPF blends seamlessly (76% of users agree)OS-01 FACE SPF is lightweight (76% of users agree)OS-01 FACE SPF absorbs easily (73% of users agree)Skin feels smoother after using OS-01 FACE SPF (71% of users agree)Skin appears more radiant after using OS-01 FACE SPF(71% of users agree)OS-01 FACE SPF sits well under makeup (71% of users agree)

Shown in a 30 day consumer perception study with 50 participants performed by a third party research organization. Participants self-reported the effects of OS-01 FACE SPF (untinted) compared to baseline.

Blending capability with different skin tones

OS-01 FACE SPF (Tinted):
  • Type I-II (n=28):
    • 78% agreed product matched seamlessly
    • 14% thought product was too dark
  • Type III-IV (n=4):
    • 75% agreed product matched seamlessly
    • 25% thought product was too dark
  • Types V-VI (n=6):
    • 33% thought tint was too light
    • 66% agreed tint matched seamlessly
OS-01 FACE SPF (Untinted):
  • Type I-II (n=16):
    • 69% agreed no white cast
    • 18% reported a white cast
  • Types III-IV (n=7):
    • 100% agreed no white cast
  • Types V-VI (n=8):
    • 37.5% agreed no white cast
    • 37.5% reported a white cast

Based on a one week beta test (consumer perception) study, performed with 31 (tinted) and 38 (non-tinted) randomly selected participants, in which participants self-reported their results after using OS-01 FACE SPF at least once daily for one week.

UVA + UVB protection

Broad Spectrum SPF 30+

Passed the Broad Spectrum Test in 21 CFR 201.327(j)

PA+++

Passed the In-Vivo UVA-PF Determination Study #23-944 Utilizing ISO 24442-2022(E)

Non-comedogenic

OS-01 FACE SPF is non-comedogenic.

Show in a four-week single-blind clinical study with 33 participants assessing the comedogenic potential of OS-01 FACE, OS-01 EYE, OS-01 FACE SPF (OS-01 SHIELD), and OS-01 BODY SPF by means of repeated occlusive cutaneous patch applications and follicular biopsy procedure. The positive control (lanolin) showed significantly higher follicular biopsy scores compared to the test products (p<0.05). When compared to the negative control (untreated site), there were no statistically significant changes in skin treated with the test products, clinically proving that the test products are non-comedogenic.

Sensitive Skin

OS-01 FACE SPF is Dermatologically Tested and Safe for Sensitive Skin.

Show in a clinical study with 54 healthy volunteers by means of repeated cutaneous occlusive patch applications, after which there were no questionable reactions observed.

Past UV Aging

OS-01 FACE SPF can undo past UV aging / reverse the effects of UV aging / repair UV aging.

Shown in lab studies by measuring a key senescence biomarker (P16) and inflammation biomarker (IL-8) on ex vivo human skin samples treated with nothing or OS-01 FACE SPF. Skin treated with OS-01 FACE SPF displayed significantly lower levels of P16 and IL-8 compared to skin with no treatment.

Antioxidant power / free radicals

OS-01 FACE SPF scavenges free radicals 4x more effectively than a leading anti-aging antioxidant SPF moisturizer.

Shown in lab studies utilizing a chemical probe with a stable radical that changes color when that radical is scavenged to measure the antioxidant capacity OS-01 FACE SPF versus a leading anti-aging antioxidant SPF moisturizer.

Inflammation

OS-01 FACE SPF protects against UV-induced inflammation (superior to regular sunscreen).

Shown in lab studies by measuring a key inflammation biomarker (IL-6) on ex vivo human skin samples (31y and 41y) treated with nothing (No Sunscreen), regular sunscreen (average drugstore sunscreen), or OS-01 FACE SPF (tinted & non-tinted), then exposed to UVB radiation. Skin treated with OS-01 FACE SPF displayed significantly lower levels of IL-6 compared to skin with no treatment and skin treated with regular sunscreen.

Cellular senescence

OS-01 FACE SPF protects against UV-induced cellular senescence (superior to regular sunscreen).

Shown in lab studies by measuring a key senescence biomarker (P16) on ex vivo human skin samples (31y and 41y) treated with nothing (No Sunscreen), regular sunscreen (average drugstore sunscreen), or OS-01 FACE SPF (tinted & non-tinted), then exposed to UVB radiation. Skin treated with OS-01 FACE SPF displayed significantly lower levels of P16 compared to skin with no treatment and skin treated with regular sunscreen.

OS-01 FACE SPF reduces cellular senescence in skin.

Shown in lab studies by measuring a key senescence biomarker (P16) on ex vivo human skin samples treated with nothing or OS-01 FACE SPF. Skin treated with OS-01 FACE SPF displayed significantly lower levels of P16 compared to skin with no treatment.

ANTIOXIDANT POWER / FREE RADICALS

OS-01 FACE SPF scavenges free radicals 4x more effectively than a leading anti-aging antioxidant SPF moisturizer.

Shown in lab studies utilizing a chemical probe with a stable radical that changes color when that radical is scavenged to measure the antioxidant capacity OS-01 FACE SPF versus a leading anti-aging antioxidant SPF moisturizer.

OS-01 FACE SPF performs similarly to common vitamin C serum at neutralizing free radicals.

Shown in lab studies by measuring levels of free radical scavenging for common vitamin C serums (popular $90 and $50 vitamin C serums) and OS-01 FACE SPF using a DPPH assay. More information can be found hereto learn more about what do antioxidants do for skin.

OS-01 FACE SPF (OS-01 SHIELD)

UVA + UVB protection

Broad Spectrum SPF 30+

Passed the Broad Spectrum Test in 21 CFR 201.327(j)
PA+++

Passed the In-Vivo UVA-PF Determination Study #23-944 Utilizing ISO 24442-2022(E)

Feel / visual benefits

Skin feels moisturized after using OS-01 FACE SPF (91% of users agree)Skin feels nourished after using OS-01 FACE SPF (87% of users agree)OS-01 FACE SPF spreads easily (80% of users agree)Skin feels more hydrated after using OS-01 FACE SPF (78% of users agree)OS-01 FACE SPF blends seamlessly (76% of users agree)OS-01 FACE SPF is lightweight (76% of users agree)OS-01 FACE SPF absorbs easily (73% of users agree)Skin feels smoother after using OS-01 FACE SPF (71% of users agree)Skin appears more radiant after using OS-01 FACE SPF(71% of users agree)OS-01 FACE SPF sits well under makeup (71% of users agree)

Shown in a 30 day consumer perception study with 50 participants performed by a third party research organization. Participants self-reported the effects of OS-01 FACE SPF (untinted) compared to baseline.

Blending capability with different skin tones

OS-01 FACE SPF (Tinted):
  • Type I-II (n=28):
    • 78% agreed product matched seamlessly
    • 14% thought product was too dark
  • Type III-IV (n=4):
    • 75% agreed product matched seamlessly
    • 25% thought product was too dark
  • Types V-VI (n=6):
    • 33% thought tint was too light
    • 66% agreed tint matched seamlessly
OS-01 FACE SPF (Untinted):
  • Type I-II (n=16):
    • 69% agreed no white cast
    • 18% reported a white cast
  • Types III-IV (n=7):
    • 100% agreed no white cast
  • Types V-VI (n=8):
    • 37.5% agreed no white cast
    • 37.5% reported a white cast

Based on a one week beta test (consumer perception) study, performed with 31 (tinted) and 38 (non-tinted) randomly selected participants, in which participants self-reported their results after using OS-01 FACE SPF at least once daily for one week.

Sunburn

OS-01 FACE SPF is more effective at protecting against UV-induced erythema (sunburn) compared to a top dermatologist recommended brand.

Shown in a clinical study performed by a third party research organization with 30 participants, measuring erythema levels on skin protected with OS-01 FACE SPF versus a top dermatologist recommended brand before and 24 hours after UV exposure.

UV-Induced Pigmentation

OS-01 FACE SPF is more effective at protecting against UV-induced pigmentation compared to a top dermatologist recommended brand.

Shown in a clinical study performed by a third party research organization with 30 participants, measuring pigmentation levels on skin protected with OS-01 FACE SPF versus a top dermatologist recommended brand before and 24 hours after UV exposure.

Non-comedogenic

OS-01 FACE SPF is non-comedogenic.

Show in a four-week single-blind clinical study with 33 participants assessing the comedogenic potential of OS-01 FACE, OS-01 EYE, OS-01 FACE SPF (OS-01 SHIELD), and OS-01 BODY SPF by means of repeated occlusive cutaneous patch applications and follicular biopsy procedure. The positive control (lanolin) showed significantly higher follicular biopsy scores compared to the test products (p<0.05). When compared to the negative control (untreated site), there were no statistically significant changes in skin treated with the test products, clinically proving that the test products are non-comedogenic.

Sensitive Skin

OS-01 FACE SPF is Dermatologically Tested and Safe for Sensitive Skin.

Show in a clinical study with 54 healthy volunteers by means of repeated cutaneous occlusive patch applications, after which there were no questionable reactions observed.

Cellular senescence

OS-01 FACE SPF protects against UV-induced cellular senescence (superior to regular sunscreen).

Shown in lab studies by measuring a key senescence biomarker (P16) on ex vivo human skin samples (31y and 41y) treated with nothing (No Sunscreen), regular sunscreen (average drugstore sunscreen), or OS-01 FACE SPF (tinted & non-tinted), then exposed to UVB radiation. Skin treated with OS-01 FACE SPF displayed significantly lower levels of P16 compared to skin with no treatment and skin treated with regular sunscreen.

OS-01 FACE SPF reduces cellular senescence in skin.

Shown in lab studies by measuring a key senescence biomarker (P16) on ex vivo human skin samples treated with nothing or OS-01 FACE SPF. Skin treated with OS-01 FACE SPF displayed significantly lower levels of P16 compared to skin with no treatment.

Inflammation

OS-01 FACE SPF protects against UV-induced inflammation (superior to regular sunscreen).

Shown in lab studies by measuring a key inflammation biomarker (IL-6) on ex vivo human skin samples (31y and 41y) treated with nothing (No Sunscreen), regular sunscreen (average drugstore sunscreen), or OS-01 FACE SPF (tinted & non-tinted), then exposed to UVB radiation. Skin treated with OS-01 FACE SPF displayed significantly lower levels of IL-6 compared to skin with no treatment and skin treated with regular sunscreen.

Past UV Aging

OS-01 FACE SPF can undo past UV aging / reverse the effects of UV aging / repair UV aging.

Shown in lab studies by measuring a key senescence biomarker (P16) and inflammation biomarker (IL-8) on ex vivo human skin samples treated with nothing or OS-01 FACE SPF. Skin treated with OS-01 FACE SPF displayed significantly lower levels of P16 and IL-8 compared to skin with no treatment.

Antioxidant power / free radicals

OS-01 FACE SPF scavenges free radicals 4x more effectively than a leading anti-aging antioxidant SPF moisturizer.

Shown in lab studies utilizing a chemical probe with a stable radical that changes color when that radical is scavenged to measure the antioxidant capacity OS-01 FACE SPF versus a leading anti-aging antioxidant SPF moisturizer.

ANTIOXIDANT POWER / FREE RADICALS

OS-01 FACE SPF scavenges free radicals 4x more effectively than a leading anti-aging antioxidant SPF moisturizer.

Shown in lab studies utilizing a chemical probe with a stable radical that changes color when that radical is scavenged to measure the antioxidant capacity OS-01 FACE SPF versus a leading anti-aging antioxidant SPF moisturizer.

OS-01 FACE SPF performs similarly to common vitamin C serum at neutralizing free radicals.

Shown in lab studies by measuring levels of free radical scavenging for common vitamin C serums (popular $90 and $50 vitamin C serums) and OS-01 FACE SPF using a DPPH assay. More information can be found hereto learn more about what do antioxidants do for skin.

OS-01 BODY SPF

Feel / visual benefits

100% of users agree OS-01 BODY SPF applies evenly and smooth.96.7% of users agree OS-01 BODY SPF feels light and weightless on their skin.76.6% of users agree their skin feels instantly hydrated upon application.83.3% of users agree OS-01 BODY SPF does not leave their skin oily/greasy.93.3% of users agree OS-01 BODY SPF does not clog their pores.93.3% of users agree OS-01 BODY SPF blends seamlessly with their skin tone.(Of Type I - IV skin tones (n=20), 100% of users agree OS-01 BODY SPF blends seamlessly with their skin tone)(Of Type V - VI skin tones (n=10), 80% of users agree OS-01 BODY SPF blends seamlessly with their skin tone)85.2% of users agree the product worked well with the rest of their skin routine.

Shown in a one week beta test (consumer perception study) performed with 30 participants
Non-Comedogenic

OS-01 BODY SPF is non-comedogenic.

Show in a four-week single-blind clinical study with 33 participants assessing the comedogenic potential of OS-01 FACE, OS-01 EYE, OS-01 FACE SPF (OS-01 SHIELD), and OS-01 BODY SPF by means of repeated occlusive cutaneous patch applications and follicular biopsy procedure. The positive control (lanolin) showed significantly higher follicular biopsy scores compared to the test products (p<0.05). When compared to the negative control (untreated site), there were no statistically significant changes in skin treated with the test products, clinically proving that the test products are non-comedogenic.

Sensitive Skin

OS-01 BODY SPF is Dermatologically Tested and Safe for Sensitive Skin.

Show in a clinical study with 54 healthy volunteers by means of repeated cutaneous occlusive patch applications, after which there were no questionable reactions observed.

UV-Induced Collagen Degradation

OS-01 BODY SPF protects skin from UV-induced collagen degradation

Shown lab studies by measuring collagen density in ex vivo human skin samples (41, 59, and 66y) that were treated with nothing (No Treatment, control) or OS-01 BODY SPF then exposed to UV radiation. Collagen density was analyzed after 24 hours. Collagen density of No Treatment + UVB decreased by 16.53%** compared to control. Collagen density of OS-01 BODY SPF + UVB increased by 8.9% compared to control. Collagen density of OS-01 BODY SPF + UVB increased by 30%*** compared to no treatment + UVB. (**p<0.01; ****p<0.0001) Discover more hereto learn more about introducing os 01 body spf.

Effects of UV aging

OS-01 BODY SPF reduces the effects of UV aging, including biomarkers associated with senescence and aging, inflammation, and collagen and hyaluronic acid breakdown.

Shown in lab studies by measuring levels of key biomarkers associated with senescence/aging (P16), inflammation (IL-8), hyaluronic acid breakdown (HYAL1) and collagen breakdown (MMP1) in ex vivo human skin samples (41y and 59y) that were treated with nothing (No Treatment) or OS-01 BODY SPF, then exposed to UV radiation. Biomarkers were analyzed after 24 hours. P16, IL-8, and HYAL1 significantly decreased in skin treated with OS-01 BODY SPF compared to No Treatment + UVB (*p<0.05, **p<0.01). The decrease in MMP-1 was not statistically significant. Discover more hereto learn more about introducing os 01 body spf.

Antioxidant Power

OS-01 BODY SPF offers superior antioxidant power compared to other “anti-aging” SPFs containing antioxidants.

Antioxidant capacity of OS-01 BODY and commonly used “anti-aging” SPFs with antioxidants were measured using a DPPH assay. Measured four separate times. Discover more hereto learn more about what do antioxidants do for skin and why should you care.

OS-01 BODY SPF

Feel / visual benefits

100% of users agree OS-01 BODY SPF applies evenly and smooth.96.7% of users agree OS-01 BODY SPF feels light and weightless on their skin.76.6% of users agree their skin feels instantly hydrated upon application.83.3% of users agree OS-01 BODY SPF does not leave their skin oily/greasy.93.3% of users agree OS-01 BODY SPF does not clog their pores.93.3% of users agree OS-01 BODY SPF blends seamlessly with their skin tone.(Of Type I - IV skin tones (n=20), 100% of users agree OS-01 BODY SPF blends seamlessly with their skin tone)(Of Type V - VI skin tones (n=10), 80% of users agree OS-01 BODY SPF blends seamlessly with their skin tone)85.2% of users agree the product worked well with the rest of their skin routine.

Shown in a one week beta test (consumer perception study) performed with 30 participants
Non-Comedogenic

OS-01 BODY SPF is non-comedogenic.

Show in a four-week single-blind clinical study with 33 participants assessing the comedogenic potential of OS-01 FACE, OS-01 EYE, OS-01 FACE SPF (OS-01 SHIELD), and OS-01 BODY SPF by means of repeated occlusive cutaneous patch applications and follicular biopsy procedure. The positive control (lanolin) showed significantly higher follicular biopsy scores compared to the test products (p<0.05). When compared to the negative control (untreated site), there were no statistically significant changes in skin treated with the test products, clinically proving that the test products are non-comedogenic.

Sensitive Skin

OS-01 BODY SPF is Dermatologically Tested and Safe for Sensitive Skin.

Show in a clinical study with 54 healthy volunteers by means of repeated cutaneous occlusive patch applications, after which there were no questionable reactions observed.

UV-Induced Collagen Degradation

OS-01 BODY SPF protects skin from UV-induced collagen degradation

Shown lab studies by measuring collagen density in ex vivo human skin samples (41, 59, and 66y) that were treated with nothing (No Treatment, control) or OS-01 BODY SPF then exposed to UV radiation. Collagen density was analyzed after 24 hours. Collagen density of No Treatment + UVB decreased by 16.53%** compared to control. Collagen density of OS-01 BODY SPF + UVB increased by 8.9% compared to control. Collagen density of OS-01 BODY SPF + UVB increased by 30%*** compared to no treatment + UVB. (**p<0.01; ****p<0.0001) Discover more hereto learn more about introducing os 01 body spf.

Effects of UV aging

OS-01 BODY SPF reduces the effects of UV aging, including biomarkers associated with senescence and aging, inflammation, and collagen and hyaluronic acid breakdown.

Shown in lab studies by measuring levels of key biomarkers associated with senescence/aging (P16), inflammation (IL-8), hyaluronic acid breakdown (HYAL1) and collagen breakdown (MMP1) in ex vivo human skin samples (41y and 59y) that were treated with nothing (No Treatment) or OS-01 BODY SPF, then exposed to UV radiation. Biomarkers were analyzed after 24 hours. P16, IL-8, and HYAL1 significantly decreased in skin treated with OS-01 BODY SPF compared to No Treatment + UVB (*p<0.05, **p<0.01). The decrease in MMP-1 was not statistically significant. Discover more hereto learn more about introducing os 01 body spf.

Antioxidant Power

OS-01 BODY SPF offers superior antioxidant power compared to other “anti-aging” SPFs containing antioxidants.

Antioxidant capacity of OS-01 BODY and commonly used “anti-aging” SPFs with antioxidants were measured using a DPPH assay. Measured four separate times. Discover more hereto learn more about what do antioxidants do for skin and why should you care.

PREP

OS-01 peptide penetration

PREP can improve peptide penetration by up to 2x.

Shown in lab studies on ex vivo human skin samples (54 yr) by comparing the amount of OS-01 peptide present in the dermis layer before and after treatment with PREP + OS-01 FACE vs OS-01 FACE alone. Data measured in triplicate.
Hydration

PREP can enhance the hydration effects of OS-01 FACE.

Shown in lab studies on ex vivo human skin samples (46 yr) by comparing levels of key skin hydration biomarker (AQP3) before and after treatment with PREP + OS-01 FACE vs OS-01 FACE alone. Data measured in triplicate.

Sensitive Skin

PREP is Dermatologically Tested and Safe for Sensitive Skin.

Show in a clinical study with 54 healthy volunteers by means of repeated cutaneous occlusive patch applications, after which there were no questionable reactions observed.

PREP

OS-01 peptide penetration

PREP can improve peptide penetration by up to 2x.

Shown in lab studies on ex vivo human skin samples (54 yr) by comparing the amount of OS-01 peptide present in the dermis layer before and after treatment with PREP + OS-01 FACE vs OS-01 FACE alone. Data measured in triplicate.
Hydration

PREP can enhance the hydration effects of OS-01 FACE.

Shown in lab studies on ex vivo human skin samples (46 yr) by comparing levels of key skin hydration biomarker (AQP3) before and after treatment with PREP + OS-01 FACE vs OS-01 FACE alone. Data measured in triplicate.

Sensitive Skin

PREP is Dermatologically Tested and Safe for Sensitive Skin.

Show in a clinical study with 54 healthy volunteers by means of repeated cutaneous occlusive patch applications, after which there were no questionable reactions observed.

Scientific Publications

IN VITRO AND IN VIVO TOXICITY ASSESSMENT OF THE SENOTHERAPEUTIC
Alessandra Zonari, Lear E.Brace, Thuany Alencar-Silva, William F.Porto, Daniel Foyt, Mylieneth Guiang, Edgar Andres Ocho Cruz, Octavio L.Franco, Carolina R. Oliveira, Mariana Boroni, Juliana L.Carvalho.
SENOTHERAPEUTIC PEPTIDE REDUCES SKIN BIOLOGICAL AGE AND IMPROVES SKIN HEALTH MARKERS
Alessandra Zonari, Lear E. Brace, Thuany Alencar-Silva, William F. Porto, Daniel Foyt, Mylieneth Guiang, Edgar Andres Ochoa Cruz, Bailey Marshall, Willian G. Salgueiro, Mehmet Dinçer Inan, Mizanur Rahman, Taslim Anupom, Siva Vanapalli, Marcelo A. Mori, Octavio L. Franco, Carolina R. Oliveira, Mariana Boroni, Juliana L. Carvalho.
IN VITRO AND IN VIVO TOXICITY ASSESSMENT OF THE SENOTHERAPEUTIC
Alessandra Zonari, Lear E.Brace, Thuany Alencar-Silva, William F.Porto, Daniel Foyt, Mylieneth Guiang, Edgar Andres Ocho Cruz, Octavio L.Franco, Carolina R. Oliveira, Mariana Boroni, Juliana L.Carvalho.
IN VITRO AND IN VIVO TOXICITY ASSESSMENT OF THE SENOTHERAPEUTIC
Alessandra Zonari PhD, Lear E. Brace PhD, Nathaniel H. O. Harder PhD, Claire Harker BA, Carolina R. Oliveira PhD, Mariana Boroni PhD, Juliana L. Carvalho PhD

Scientific Publications

IN VITRO AND IN VIVO TOXICITY ASSESSMENT OF THE SENOTHERAPEUTIC
Alessandra Zonari, Lear E.Brace, Thuany Alencar-Silva, William F.Porto, Daniel Foyt, Mylieneth Guiang, Edgar Andres Ocho Cruz, Octavio L.Franco, Carolina R. Oliveira, Mariana Boroni, Juliana L.Carvalho.
SENOTHERAPEUTIC PEPTIDE REDUCES SKIN BIOLOGICAL AGE AND IMPROVES SKIN HEALTH MARKERS
Alessandra Zonari, Lear E. Brace, Thuany Alencar-Silva, William F. Porto, Daniel Foyt, Mylieneth Guiang, Edgar Andres Ochoa Cruz, Bailey Marshall, Willian G. Salgueiro, Mehmet Dinçer Inan, Mizanur Rahman, Taslim Anupom, Siva Vanapalli, Marcelo A. Mori, Octavio L. Franco, Carolina R. Oliveira, Mariana Boroni, Juliana L. Carvalho.
IN VITRO AND IN VIVO TOXICITY ASSESSMENT OF THE SENOTHERAPEUTIC
Alessandra Zonari, Lear E.Brace, Thuany Alencar-Silva, William F.Porto, Daniel Foyt, Mylieneth Guiang, Edgar Andres Ocho Cruz, Octavio L.Franco, Carolina R. Oliveira, Mariana Boroni, Juliana L.Carvalho.
IN VITRO AND IN VIVO TOXICITY ASSESSMENT OF THE SENOTHERAPEUTIC
Alessandra Zonari PhD, Lear E. Brace PhD, Nathaniel H. O. Harder PhD, Claire Harker BA, Carolina R. Oliveira PhD, Mariana Boroni PhD, Juliana L. Carvalho PhD